Published in J Acquir Immune Defic Syndr on April 01, 2002
EFV/FTC/TDF-associated hepatotoxicity: a case report and review. AIDS Patient Care STDS (2013) 0.89
Assessment of HBV flare in a randomized clinical trial in HIV/HBV coinfected subjects initiating HBV-active antiretroviral therapy in Thailand. AIDS Res Ther (2012) 0.80
Effect of anemia on hepatotoxicity of HAART in HIV patients in Benin city. Niger Med J (2011) 0.77
Drug-Induced Liver Injury in HIV Patients. Gastroenterol Hepatol (N Y) (2006) 0.75
Association of Abnormal Liver Function Parameters with HIV Serostatus and CD4 Count in Antiretroviral-Naive Rwandan Women. AIDS Res Hum Retroviruses (2015) 0.75
Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med (2004) 9.72
Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis (2013) 3.30
A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol (2008) 2.97
Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a U.S.-Canadian multicenter study. J Hepatol (2007) 2.58
Risk factors and treatment outcomes in osteomyelitis. J Antimicrob Chemother (2003) 2.48
Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. Gastroenterology (2004) 2.28
Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial. Ann Intern Med (2013) 2.25
Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin Gastroenterol Hepatol (2007) 2.16
Interferon alfa-2b [correction of alpha-2b]and ribavirin for patients with chronic hepatitis C and normal ALT. Am J Gastroenterol (2004) 2.12
A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol (2006) 1.92
Liver fibrosis during an outbreak of acute hepatitis C virus infection in HIV-infected men: a prospective cohort study. J Infect Dis (2008) 1.78
A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin. Gastroenterology (2010) 1.70
Outcomes of osteomyelitis among patients treated with outpatient parenteral antimicrobial therapy. Am J Med (2003) 1.69
A treatment algorithm for the management of chronic hepatitis B virus infection in the United States. Clin Gastroenterol Hepatol (2004) 1.47
Diabetes mellitus and advanced liver fibrosis are risk factors for severe anaemia during telaprevir-based triple therapy. Liver Int (2013) 1.43
Sustained virologic response with short-course ribavirin and peginterferon treatment in 2 patients coinfected with HIV and HCV genotype 1. AIDS Read (2006) 1.38
Acute HIV seroconversion in a patient receiving pegylated interferon for treatment of hepatitis C. AIDS Read (2003) 1.38
Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy. Hepatology (2004) 1.30
Chronic hepatitis B: preventing, detecting, and managing viral resistance. Clin Gastroenterol Hepatol (2008) 1.29
Hepatitis Outreach Network: a practical strategy for hepatitis screening with linkage to care in foreign-born communities. J Hepatol (2013) 1.25
Risk of immune recovery uveitis in patients with AIDS and cytomegalovirus retinitis. Ophthalmology (2006) 1.20
Short communication: Inadequate vitamin D exacerbates parathyroid hormone elevations in tenofovir users. AIDS Res Hum Retroviruses (2010) 1.08
Mortality in hepatitis C virus-infected patients with a diagnosis of AIDS in the era of combination antiretroviral therapy. Clin Infect Dis (2012) 1.08
Interferon-induced depression and cognitive impairment in hepatitis C virus patients: a 72 week prospective study. AIDS (2005) 1.08
Costs of telaprevir-based triple therapy for hepatitis C: $189,000 per sustained virological response. Hepatology (2014) 1.05
Acute pancreatitis associated with interferon and ribavirin therapy in patients with chronic hepatitis C. Dig Dis Sci (2004) 1.04
Management of hepatitis C virus in special populations: patient and treatment considerations. Clin Gastroenterol Hepatol (2005) 1.01
Toxicity of non-nucleoside analogue reverse transcriptase inhibitors. Semin Liver Dis (2003) 1.00
Effect of baseline CD4 cell count on the efficacy and safety of peginterferon Alfa-2a (40KD) plus ribavirin in patients with HIV/hepatitis C virus coinfection. J Acquir Immune Defic Syndr (2008) 0.97
HIV and liver diseases: recent clinical advances. Clin Liver Dis (2005) 0.96
Intrahepatic CD4+ cell depletion in hepatitis C virus/HIV-coinfected patients. J Acquir Immune Defic Syndr (2004) 0.95
Management of chronic hepatitis C virus in patients with HIV. Curr Treat Options Gastroenterol (2005) 0.95
Clinical factors that predict noncirrhotic portal hypertension in HIV-infected patients: a proposed diagnostic algorithm. J Infect Dis (2013) 0.94
HIV/hepatitis C virus-coinfected patients and cirrhosis: how to diagnose it and what to do next? Clin Infect Dis (2013) 0.93
The development of hepatoportal sclerosis and portal hypertension due to didanosine use in HIV. Virchows Arch (2010) 0.93
Telaprevir in the treatment of acute hepatitis C virus infection in HIV-infected men. Clin Infect Dis (2013) 0.90
Stability of CXCL-8 and related AU-rich mRNAs in the context of hepatitis C virus replication in vitro. J Infect Dis (2006) 0.88
Rapid progression to decompensated cirrhosis, liver transplant, and death in HIV-infected men after primary hepatitis C virus infection. Clin Infect Dis (2012) 0.88
Genetic analysis of interferon induced thyroiditis (IIT): evidence for a key role for MHC and apoptosis related genes and pathways. J Autoimmun (2013) 0.87
The critical role of medication adherence in the success of boceprevir and telaprevir in clinical practice. J Hepatol (2011) 0.86
The era of direct-acting antivirals has begun: the beginning of the end for HCV? Semin Liver Dis (2011) 0.86
Current status of the use of growth factors and other adjuvant medications in patients receiving peginterferon and ribavirin. Rev Gastroenterol Disord (2004) 0.86
Epoetin alfa once weekly improves anemia in HIV/hepatitis C virus-coinfected patients treated with interferon/ribavirin: a randomized controlled trial. J Acquir Immune Defic Syndr (2005) 0.85
Hepatic steatosis in HIV/HCV co-infected patients: correlates, efficacy and outcomes of anti-HCV therapy: a paired liver biopsy study. J Hepatol (2008) 0.85
Baseline factors prognostic of sustained virological response in patients with HIV-hepatitis C virus co-infection. AIDS (2007) 0.85
Effect of switching to tenofovir with emtricitabine in patients with chronic hepatitis B failing to respond to an adefovir-containing regimen. Eur J Gastroenterol Hepatol (2006) 0.84
Alcoholic Hepatitis. Curr Treat Options Gastroenterol (2004) 0.84
HBV plus HCV, HCV plus HIV, HBV plus HIV. Curr Gastroenterol Rep (2006) 0.83
Insulin resistance predicts re-treatment failure in an efficacy study of peginterferon-α-2a and ribavirin in HIV/HCV co-infected patients. J Hepatol (2010) 0.82
Early-onset liver fibrosis due to primary hepatitis C virus infection is higher over time in HIV-infected men. Clin Infect Dis (2012) 0.82
Daily versus thrice-weekly interferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected persons: a multicenter randomized controlled trial. J Acquir Immune Defic Syndr (2004) 0.81
Hepatitis C direct-acting antiviral agents: changing the paradigm of hepatitis C treatment in HIV-infected patients. J Clin Gastroenterol (2014) 0.79
Cost-effectiveness of peginterferon alfa-2a (40kDa) plus ribavirin in patients with HIV and hepatitis C virus co-infection. J Clin Virol (2006) 0.79
HIV-hepatitis C virus co-infection in the era of direct-acting antivirals. Curr HIV/AIDS Rep (2014) 0.79
Septic bursitis, a potential complication of protease inhibitor use in hepatitis C virus. Clin Infect Dis (2013) 0.77
Treatment of hepatitis C virus in HIV patients: a review. AIDS (2005) 0.77
Evaluation of hepatitis C virus as a risk factor for HIV-associated neuroretinal disorder. Clin Infect Dis (2013) 0.77
The HIV/HCV-coinfected patient and new treatment options. Clin Liver Dis (2011) 0.76
Hepatitis C screening beyond CDC guidelines in an Egyptian immigrant community. Liver Int (2013) 0.76
Treating HCV in HIV 2013: on the cusp of change. Liver Int (2014) 0.76
Hepatitis B: the immaculate infection. Gastroenterol Hepatol (N Y) (2007) 0.76
Update on combinations of DAAs with and without pegylated-interferon and ribavirin: triple and quadruple therapy more than doubles SVR. Clin Liver Dis (2013) 0.76
A great time to invest in baby Boomer's hepatitis C! Hepatology (2012) 0.75
Editorial comment: a tale of two viruses. AIDS Read (2002) 0.75
Trends in Liver Transplantation in Hepatitis C Virus-Infected Persons, United States. Emerg Infect Dis (2016) 0.75
Editorial comment: liver disease in the HIV-infected patient--the courage to treat. AIDS Read (2003) 0.75
MELD score and antibiotics use are predictors of length of stay in patients hospitalized with hepatic encephalopathy. BMC Gastroenterol (2014) 0.75
Editorial comment: HIV and HBV coinfection--a coming-of-age in treatment strategies. AIDS Read (2004) 0.75
Treatment of acute hepatitis C in an HIV-positive man with pegylated interferon and ribavirin for 24 weeks. AIDS Read (2007) 0.75
Hepatitis C management in HIV infection--where is the controversy? AIDS Read (2002) 0.75
Management and diagnosis of fatty liver disease. Expert Rev Gastroenterol Hepatol (2015) 0.75
Hepatitis C in HIV-infected patients: impact of direct-acting antivirals. Drugs (2014) 0.75
Hepatitis B therapies and antiviral resistance detection and management. Expert Rev Gastroenterol Hepatol (2009) 0.75
Interferon-free regimens for hepatitis C: combine and conquer. BioDrugs (2014) 0.75
The pharmacokinetic evaluation of boceprevir for treatment of hepatitis C virus. Expert Opin Drug Metab Toxicol (2013) 0.75
Antiretroviral and anti-hepatitis C virus direct-acting antiviral-related hepatotoxicity. Clin Liver Dis (2013) 0.75
The challenge of hepatitis C and HIV co-infection. Body Posit (2005) 0.75
Pegylated-IFNα2a for HIV/hepatitis C virus coinfected patients: out with the old, in with the new. Expert Opin Biol Ther (2014) 0.75